Gene · 1146
CHRNG: cholinergic receptor nicotinic gamma subunit
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CHRNG: cholinergic receptor nicotinic gamma subunit. Genes, record 1146. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1146
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P07510 | Acetylcholine receptor subunit gamma | 517 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents28
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 41258 | P07510 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 41259 | P07510 | Espacenet |
| EP 4670794 A2 | 2025-12-31 | 25 | P07510 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 19751 | P07510 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 946 | P07510 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 946 | P07510 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 19751 | P07510 | Espacenet |
| EP 4551941 A2 | 2025-05-14 | 47 | P07510 | Espacenet |
| US 12011480 B2 | 2024-06-18 | 25 | P07510 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 15086 | P07510 | Espacenet |
1 to 10 of 28
See all 28 patentsDrugs28
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATRACURIUM | CHEMBL1360 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| ATRACURIUM BESYLATE | CHEMBL1200527 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| CISATRACURIUM | CHEMBL1201248 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| CISATRACURIUM BESYLATE | CHEMBL1200641 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| DECAMETHONIUM | CHEMBL1190 | Muscle-type nicotinic acetylcholine receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| DECAMETHONIUM BROMIDE | CHEMBL1134 | Muscle-type nicotinic acetylcholine receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| DOXACURIUM | CHEMBL1237123 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| DOXACURIUM CHLORIDE | CHEMBL1237099 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| GALLAMINE | CHEMBL360055 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| GALLAMINE TRIETHIODIDE | CHEMBL1200993 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 28
See all 28 drugsTrials47
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07271472 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT07143799 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT07121699 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT07035301 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT07033442 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT06714981 | ROCURONIUM BROMIDE | ClinicalTrials.gov | ||
| NCT06514209 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT06214169 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT06212492 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT06203405 | CISATRACURIUM | ClinicalTrials.gov |
1 to 10 of 47
See all 47 trialsNIH grants275
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CHRNG papers | Newest fiscal year |
|---|---|---|---|
| P50HD105351 | Boston Children's Hospital/HMS Intellectual and Developmental Disabilities Research Center | 2 | 2025 |
| KL2TR001862 | Institutional Career Development Core | 1 | 2025 |
| P01CA196569 | Statistical Methods for Integrative Genomics in Cancer | 1 | 2025 |
| P01HL141084 | Multiscale Systems to Elucidate Susceptibility and Cardioprotective Mechanisms in Cardio-oncology | 1 | 2025 |
| P20GM103427 | Nebraska Research Network in Functional Genomics | 1 | 2025 |
| P20GM103446 | Delaware INBRE | 1 | 2025 |
| P30AG021332 | Wake Forest Claude D. Pepper OAIC - Renewal | 1 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 1 | 2025 |
| P30CA012197 | Cancer Center Support Grant | 1 | 2025 |
| P30ES029067 | Texas A&M Center for Environmental Health Research (TiCER) | 1 | 2025 |
1 to 10 of 275Source NIH's project files
See all 275 nih grantsPapers297
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrating machine learning and pharmacogenomics for biomarker discovery, identification and prioritization of potential drug candidates in ovarian cancer. | SAR QSAR Environ Res | 2026 | 42253090 | PubTator, text mining | PubMed |
| Non-pterygium Escobar syndrome from compound-heterozygous CHRNG variants: genotype-phenotype insights. | Hum Genome Var | 2026 | 41826296 | PubTator, text mining | PubMed |
| Health risk analysis of micro-and nanoplastic exposure via the microbiota-gut-brain axis. | Front Immunol | 2026 | 41789083 | PubTator, text mining | PubMed |
| Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy. | Cell Death Dis | 2026 | 41633975 | PubTator, text mining | PubMed |
| Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification. | J Pathol | 2026 | 41537454 | PubTator, text mining | PubMed |
| Biallelic CRELD1 variants cause severe muscle weakness and infantile epilepsy. | Brain Commun | 2025 | 40980404 | PubTator, text mining | PubMed |
| Dual molecular genetic diagnosis with combined malonic and methylmalonic aciduria (CMAMMA): implications of coexisting genetic disorders on clinical presentation. | J Pediatr Endocrinol Metab | 2025 | 40960910 | PubTator, text mining | PubMed |
| Persistent Inflammation, Maladaptive Remodeling, and Fibrosis in the Kidney Following Long COVID-like MHV-1 Mouse Model. | Diseases | 2025 | 40863220 | PubTator, text mining | PubMed |
| Fetal Akinesia/Hypokinesia and Arthrogryposis of Neuromuscular Origin: Etiologic Groups, Genetics, and Phenotypic Spectrum. | Ann Clin Transl Neurol | 2025 | 40443119 | PubTator, text mining | PubMed |
| Trophic Factors in Muscle-Nerve Cross-Talk Signaling Augment Muscle Fiber and Motor Endplate Development. | J Cell Physiol | 2025 | 39987522 | PubTator, text mining | PubMed |
1 to 10 of 297
See all 297 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1146
GET https://conductscience.org/api/genes/v1/1146/patents?page=2